Sigma-Aldrich

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald

Retrieved on: 
星期二, 五月 7, 2024
Commercial, Sigma-Aldrich, Business development, Vaccine, CDMO, Scorpius, Marketing, Messenger, GMP, Spacecraft

DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development.

Key Points: 
  • DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the appointment of Shari Udoff-McDonald as VP of Business Development.
  • She brings more than 25 years of experience in biopharma business development and management.
  • Joe Payne, Scorpius’ President and COO, said, “Shari has the unique combination of experience in the field, at the account-level, and in leadership roles.
  • This wide breadth of business development experience will help Scorpius continue to grow its customer base.

NIIMBL announces 63 students for the 2024 NIIMBL eXperience

Retrieved on: 
星期二, 四月 30, 2024
University, Museum, Outline of health sciences, Experience, Sigma-Aldrich, Eli Lilly, North Carolina State University, Student, JIB, Santa Clara University, NIIMBL, Thomas Jefferson University, BTEC, Merck, University of Houston, Growth, Management

NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program's launch in 2019.

Key Points: 
  • NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience, the largest cohort since the Program's launch in 2019.
  • The NIIMBL eXperience is a week-long, all-expenses-paid immersion program designed to introduce underrepresented groups including Black, Latinx, and Indigenous students completing their first or second year of college to career possibilities in the biopharmaceutical industry.
  • "The NIIMBL eXperience has been a cornerstone of our efforts to expand and diversify talent pipelines for the biopharmaceutical industry," said John Balchunas, NIIMBL Workforce Director.
  • Since 2019, the NIIMBL eXperience has served 80 students from 69 different academic institutions.

Particle Dynamics Appoints New CFO as it Advances its Strategic Growth Plans

Retrieved on: 
星期二, 四月 23, 2024
Health Technology, Pharmaceutical, Health, Sigma-Aldrich, Microsoft Dynamics 365, Merck Group, Particle, OSD, Knowledge, Avadel Pharmaceuticals, Growth, Strategic planning, Management

Mike's appointment marks a significant milestone for Particle Dynamics, underscoring the company’s commitment to delivering enhanced value to clients and stakeholders.

Key Points: 
  • Mike's appointment marks a significant milestone for Particle Dynamics, underscoring the company’s commitment to delivering enhanced value to clients and stakeholders.
  • His proven track record in financial leadership and strategic planning will be instrumental in driving Particle Dynamics’ continued growth and success in the pharmaceutical and healthcare industries.
  • Nicolas Fortin, CEO of Particle Dynamics, said: “Mike’s extensive experience and financial leadership make him the ideal candidate to lead our finance team during this exciting period of growth and expansion.
  • I am confident Mike’s strategic vision will be invaluable as we continue to strengthen our position as a global leader in particle processing and delivery technologies."

NeoGenomics Announces Senior Leadership Promotions

Retrieved on: 
星期四, 四月 18, 2024
Medical Devices, Hospitals, Genetics, Health Technology, Biotechnology, Other Health, Health, General Health, Oncology, Harvard Law School, Suffolk University, University, Political science, LIMS, Sigma-Aldrich, Ortho Clinical Diagnostics, Senior, JD, Qualcomm, SomaLogic, NEO, Marketing, Rock (geology), MBA, Growth, Management

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.

Key Points: 
  • NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately.
  • “Warren and Melody have shown exceptional leadership and performance in their respective roles," said Chris Smith, CEO of NeoGenomics.
  • “As we enter our next phase of growth, these senior leadership appointments should drive operational efficiencies, strengthen commercial synergies, and accelerate innovation through R&D.
  • Prior to NeoGenomics, Stone served as President of Americas at Ortho Clinical Diagnostics and Senior Vice President, Life Sciences Division for MilliporeSigma.

MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour

Retrieved on: 
星期三, 四月 17, 2024
Education, Science, Other Science, Primary, Secondary, Merck Group, Sigma-Aldrich, Student, Transformation, Multimedia, Merck, Tourism

MilliporeSigma’s goal is to engage 45,000 students to increase access to hands-on STEM education for students through interactive science experiences.

Key Points: 
  • MilliporeSigma’s goal is to engage 45,000 students to increase access to hands-on STEM education for students through interactive science experiences.
  • View the full release here: https://www.businesswire.com/news/home/20240417283942/en/
    MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube Tour (Photo: Business Wire)
    “Recent data shows students between 8 and 13 years old are interested in science and math, with most calling these subjects fun and exciting.
  • Students also meet our employees, who can be role models for the incredible range of STEM careers that are possible.”
    For the 2024 tour, the Curiosity Cube is sporting a new look, displaying photos of young scientists who are children of MilliporeSigma employees.
  • To learn more about the Curiosity Cube mobile science lab and view the 2024 tour schedule, visit TheCuriosityCube.com and follow the Curiosity Cube on Instagram @curiositycube_milliporesigma.

MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety Testing

Retrieved on: 
星期二, 四月 16, 2024
Biotechnology, Pharmaceutical, Health, FDA, Merck Group, Investment, Risk, Sigma-Aldrich, Software suite, Automation, Multimedia, GMP, Merck

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.

Key Points: 
  • MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.
  • The Aptegra™ CHO genetic stability assay leverages whole genome sequencing and bioinformatics to significantly accelerate biosafety testing for clients and therefore, their move into commercial production.
  • The Aptegra™ platform transforms biosafety testing with a digital solution using next-generation sequencing.”
    Currently, FDA guidance requires biotech companies to use multiple assays to address genetic stability requirements.
  • Its global biosafety testing network includes sites in Shanghai, China; Singapore; Stirling and Glasgow, UK; and Rockville, MD, USA.

NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects

Retrieved on: 
星期二, 四月 9, 2024
Project, University, Sigma-Aldrich, Pfizer, University of California, Agilent Technologies, NIIMBL, Workforce, Government, IPP, Janssen Pharmaceuticals, Organization, Fine chemical

The projects align with areas of need identified by NIIMBL and industry stakeholders.

Key Points: 
  • The projects align with areas of need identified by NIIMBL and industry stakeholders.
  • "We are excited to expand our diverse project portfolio with these innovative new projects," said Chris Roberts, Associate Institute Director.
  • Among the eight projects are two workforce development projects focused on data analytics training and strengthening the pipeline of neurodiverse talent.
  • NIIMBL is composed of nearly 200 member organizations from academia, industry, government, and non-profit organization with a common goal to advance biopharmaceutical manufacturing.

Kytopen announces appointment of industry executive Kevin Gutshall as Chief Commercial Officer

Retrieved on: 
星期一, 四月 8, 2024
Bias, Millersville University of Pennsylvania, Marketing, Sigma-Aldrich, Management

and DENVER, April 8, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, today announced the appointment of Kevin Gutshall as Chief Commercial Officer, effective April 1st, 2024.

Key Points: 
  • and DENVER, April 8, 2024 /PRNewswire/ -- Kytopen Corp., a leader in the development of manufacturing platforms and workflows for advanced therapeutic medicines, today announced the appointment of Kevin Gutshall as Chief Commercial Officer, effective April 1st, 2024.
  • Mr. Gutshall will lead the commercialization and marketing of Kytopen's Flowfect Discover™ and Flowfect Tx™ platforms.
  • "Kytopen is poised to deliver a platform that dramatically transforms the scale and yield that current advanced therapeutic medicine developers are achieving," said Mr. Gutshall, Chief Commercial Officer.
  • Kytopen recently announced the launch of their customer centric Technology Access Program as part of the overall commercial strategy for the deployment of the Flowfect Tx™ platform.

MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in Korea

Retrieved on: 
星期三, 三月 20, 2024
Research, Commercial Building & Real Estate, Construction & Property, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Public, Health care, Merck, Messenger, Merck Group, Multimedia, Vaccine, Sigma-Aldrich, Pharmaceutical industry

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.

Key Points: 
  • MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.
  • The new site is the largest investment by the company’s Life Science business sector in Asia-Pacific to date and demonstrates its commitment to expanding its capacities in the fast-growing region.
  • The investment is expected to create approximately 300 additional jobs by the end of 2028.
  • Established in 1989, the Life Science business of Merck KGaA, Darmstadt, Germany in Korea has been consistently driving dynamic growth of the science and technology industries with more than 1,700 employees across Life Science, Healthcare and Electronics.